Here's a summary of key points I took from the conference call:
- FDA approval for treatment of both 2nd and 3rd degree burns.
- USA is largest healthcare and burns treatment market globally
- First PMA granted by FDA for burns in over 2 decades
- No requirement for further trials – but Avita plans trials anyway
- 7000 patients treated to date.
- Quote from an investment group to avita team: “our team is astounded at the level of data you have compared to others in the burn and wound healing space”
- Significant portion of $50 million still to be received from BARDA – funding trials with objective for future procurement; timing to be announced.
- 500,000 burn treatments annually USA
- $5billion a year spent treating burns
- Next largest burns market, Germany, only 16% of USA
- Economic modelling – using in 2nd and in combination for 3rd >44% reduction in costs for large burns. $13 million saving for a 200 bed burns centre using recell.
Avita estimates initial target of USD $200 million market.- Other markets than burns to follow
- Prep for launch:
- recruitment of sales and marketing leaders with experience in burns;
- promotional materials
- sales team recruitment to be completed
- formally launch Q4 2018
- details of launch to be released to market over next 60 days
- planned costing per device of $$5,000 to $10,000
- 1 kit per 10% total body surface area
- Clarification of what a “pre-market approval” means – it is a full market approval; this is the type of approval needed when no other device exists on the market that can be compared to
- Avita not aware of Renovacare being very active in R&D: only spending about $300,000/year. No real clinical trials in place. [Implication seems to be Renovacare is not seen as being serious about actually getting a product to market]
- In the US health system, treatment of burns is paid to hospitals per square cm burns. No specific reimbursement is made for the device costs – so so systems need to be established for reimbursement.
- Ongoing investigation of ways to improve the usability of the product (e.g., to require less clinician time to apply treatment)
- Cash burn over next 12 months will depend on how aggressively marketing proceeds. Expect to have a better estimate of this over next 60 days
- Level of US burn specialist awareness of recell characterised as “High” … “A very big buzz going on in the United States about the availability of ReCell”. First major development in burns care in past 2 decades.
- Answering why up-take in areas with existing approval (e.g., Australia, with TGA approval) has been low, answered that this is the first time there has been a body of randomised controlled trials that would be acceptable to physicians to change standards of care. Previously only had case studies; these trials confirm at least equivalent outcomes while cutting treatment costs.
- Forums
- ASX - By Stock
- AVH
- Enlightenment
Enlightenment, page-47
-
-
- There are more pages in this discussion • 41 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add AVH (ASX) to my watchlist
(20min delay)
|
|||||
Last
$2.80 |
Change
-0.030(1.06%) |
Mkt cap ! $197.1M |
Open | High | Low | Value | Volume |
$2.83 | $2.89 | $2.80 | $299.8K | 105.3K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 3700 | $2.79 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$2.83 | 10724 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 700 | 2.790 |
1 | 2400 | 2.780 |
1 | 500 | 2.770 |
1 | 2000 | 2.760 |
1 | 4000 | 2.750 |
Price($) | Vol. | No. |
---|---|---|
2.830 | 10724 | 2 |
2.870 | 14722 | 3 |
2.880 | 14249 | 3 |
2.890 | 9500 | 1 |
2.900 | 5050 | 4 |
Last trade - 16.10pm 13/09/2024 (20 minute delay) ? |
Featured News
AVH (ASX) Chart |
The Watchlist
LPM
LITHIUM PLUS MINERALS LTD.
Simon Kidston, Non--Executive Director
Simon Kidston
Non--Executive Director
SPONSORED BY The Market Online